Q-omics provides the consensus-scored REX1BD profile across patient tissues and cancer cell-line models. REX1BD expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, REX1BD is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, REX1BD RNA expression shows 18,308 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight ACC, COAD, and THYM as cancer lineages where REX1BD shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for REX1BD — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes REX1BD survival associations across molecular data types. REX1BD RNA expression shows survival associations in the most cancer types (19), followed by mutation status (3) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible REX1BD RNA expression–survival associations across cancer types. High REX1BD expression shows unfavorable associations in ACC, UVM, KIRC and LGG, but favorable associations in HNSC and PAAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for REX1BD RNA expression.
This table summarizes REX1BD tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 3. The strongest signals are observed in COAD for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for REX1BD. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. REX1BD shows higher tumor expression in COAD, HNSC, KIRC, STAD, LIHC and READ. The COAD box plot shows higher REX1BD RNA expression in tumor versus normal tissue (log2 FC = +1.454, t-test p < 0.001).
This table shows molecular features associated with REX1BD in patient tissues and cancer cell lines. In patient samples, REX1BD shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, REX1BD RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and SKIN.
